Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

BACKGROUND: Adjuvant chemotherapy for resected early stage NSCLC provides modest survival benefit. Bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor, improves outcomes when added to platinum-based chemotherapy in advanced stage non-squamous NSCLC. We conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakelee, Heather A., Dahlberg, Suzanne E., Keller, Steven M., Tester, William J., Gandara, David R., Graziano, Stephen L., Adjei, Alex, Leighl, Natasha B., Aisner, Seena C., Rothman, Jan M., Patel, Jyoti D., Sborov, Mark D., McDermott, Sean R., Perez-Soler, Roman, Traynor, Anne M., Butts, Charles, Evans, Tracey, Shafqat, Atif, Chapman, Andrew E., Kasbari, Samer S., Horn, Leora, Ramalingam, Suresh S., Schiller, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789803/
https://www.ncbi.nlm.nih.gov/pubmed/29129443
http://dx.doi.org/10.1016/S1470-2045(17)30691-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789803/
https://www.ncbi.nlm.nih.gov/pubmed/29129443
http://dx.doi.org/10.1016/S1470-2045(17)30691-5

Ejemplares similares